{"id":"vehicle-tid","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a vehicle, it is used as a control group in clinical trials and does not have a specific therapeutic effect.","oneSentence":"Vehicle (TID) is a treatment that does not have a known mechanism of action.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:40:27.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06244316","phase":"PHASE2","title":"A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2024-01-22","conditions":"Dry Eye Disease","enrollment":317},{"nctId":"NCT05066997","phase":"PHASE2, PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2021-10-19","conditions":"Diabetic Macular Edema","enrollment":552},{"nctId":"NCT06172257","phase":"PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2024-03-15","conditions":"Diabetic Macular Edema","enrollment":401},{"nctId":"NCT06954597","phase":"PHASE2","title":"Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis","status":"RECRUITING","sponsor":"Topadur Pharma AG","startDate":"2025-02-04","conditions":"Digital Ulcers in Systemic Sclerosis","enrollment":15},{"nctId":"NCT07245017","phase":"EARLY_PHASE1","title":"JN002 for the Treatment of Dry Eye Disease","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-11-24","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT05136170","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-01-27","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT06833320","phase":"PHASE1, PHASE2","title":"Propranolol Treatment for Postoperative Chylothorax","status":"RECRUITING","sponsor":"June Wu","startDate":"2025-09-09","conditions":"Postoperative Chylothorax, Congenital Heart Disease, Open Heart Surgery","enrollment":50},{"nctId":"NCT05454956","phase":"PHASE2","title":"Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD","status":"COMPLETED","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2022-08-03","conditions":"Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation","enrollment":39},{"nctId":"NCT05636228","phase":"PHASE2","title":"Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis","status":"COMPLETED","sponsor":"Invirsa, Inc.","startDate":"2023-06-09","conditions":"Acute Infectious Keratoconjunctivitis","enrollment":93},{"nctId":"NCT06482671","phase":"PHASE3","title":"Primary Care dySpEpsia rikkuNshiTo","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2024-10-01","conditions":"Dyspepsia and Other Specified Disorders of Function of Stomach, Postprandial Distress Syndrome","enrollment":100},{"nctId":"NCT05896670","phase":"PHASE2","title":"Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Oculis","startDate":"2023-11-29","conditions":"Dry Eye Disease","enrollment":122},{"nctId":"NCT06969495","phase":"NA","title":"Pilot Clinical Study Testing Tiger Milk Mushroom Gel (Lignosus Rhinocerus TM02®) for Treating Mouth Ulcers","status":"COMPLETED","sponsor":"Mahsa University","startDate":"2023-02-01","conditions":"Mouth Ulcer","enrollment":21},{"nctId":"NCT04391894","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-10-06","conditions":"Dry Eye","enrollment":718},{"nctId":"NCT05201170","phase":"PHASE3","title":"A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye","status":"COMPLETED","sponsor":"Palatin Technologies, Inc","startDate":"2021-12-30","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":575},{"nctId":"NCT05133180","phase":"PHASE3","title":"Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-01-19","conditions":"Dry Eye","enrollment":104},{"nctId":"NCT03982368","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2019-06-10","conditions":"Dry Eye Syndrome","enrollment":261},{"nctId":"NCT05586152","phase":"PHASE1, PHASE2","title":"Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease","status":"COMPLETED","sponsor":"Invirsa, Inc.","startDate":"2022-08-30","conditions":"Dry Eye Disease","enrollment":84},{"nctId":"NCT06054217","phase":"PHASE2","title":"Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2023-08-01","conditions":"Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis","enrollment":36},{"nctId":"NCT04088318","phase":"PHASE2","title":"A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients","status":"UNKNOWN","sponsor":"OnQuality Pharmaceuticals (USA) LLC","startDate":"2019-12-09","conditions":"Hand-Foot Skin Reaction (HFSR)","enrollment":170},{"nctId":"NCT04470752","phase":"PHASE2","title":"Capsaicin for Post-stroke Dysphagia","status":"UNKNOWN","sponsor":"Georg Kägi, MD","startDate":"2021-08-24","conditions":"Dysphagia, Late Effect of Stroke","enrollment":82},{"nctId":"NCT04511650","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019","status":"TERMINATED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2020-10-21","conditions":"COVID-19, Acute Respiratory Distress Syndrome (ARDS)","enrollment":31},{"nctId":"NCT02811783","phase":"PHASE3","title":"Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL","status":"TERMINATED","sponsor":"Elorac, Inc.","startDate":"2017-01","conditions":"Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Sézary Syndrome","enrollment":59},{"nctId":"NCT04130204","phase":"PHASE2","title":"Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)","status":"COMPLETED","sponsor":"Dyve Biosciences, Inc.","startDate":"2020-02-12","conditions":"Gout","enrollment":284},{"nctId":"NCT04541888","phase":"PHASE3","title":"Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease","status":"COMPLETED","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2020-11-05","conditions":"Dry Eye","enrollment":644},{"nctId":"NCT05262179","phase":"PHASE1","title":"A Phase 1 Clinical Trial to Explore Systemic Exposure of CTO0101 Eye Drops, Safety and Local Tolerability in Healthy Adults","status":"UNKNOWN","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2021-10-05","conditions":"Healthy","enrollment":16},{"nctId":"NCT05036174","phase":"NA","title":"Diphenhydramine Ointment for Knee Osteoarthritis","status":"UNKNOWN","sponsor":"Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology","startDate":"2021-09","conditions":"Osteoarthritis","enrollment":30},{"nctId":"NCT04995354","phase":"PHASE2, PHASE3","title":"Efficacy of EGF-loaded Self Healing Gel in Treatment of Oral Mucositis","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-06-01","conditions":"Oral Mucositis","enrollment":90},{"nctId":"NCT03829917","phase":"PHASE2, PHASE3","title":"Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"Fundacion Nacional de Dermatologia","startDate":"2019-02-01","conditions":"Cutaneous Leishmaniasis, American","enrollment":120},{"nctId":"NCT02786901","phase":"PHASE3","title":"LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2016-06","conditions":"Cataract, Pain, Ocular Inflammation","enrollment":600},{"nctId":"NCT02855450","phase":"PHASE1","title":"Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2016-12","conditions":"Glaucoma","enrollment":60},{"nctId":"NCT03533244","phase":"PHASE2","title":"A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia","status":"COMPLETED","sponsor":"Allgenesis Biotherapeutics Inc.","startDate":"2018-10-11","conditions":"Pterygium","enrollment":64},{"nctId":"NCT02165605","phase":"NA","title":"HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2012-08","conditions":"Breast Cancer","enrollment":28},{"nctId":"NCT01996839","phase":"PHASE3","title":"Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-12","conditions":"Inflammation, Pain, Cataract","enrollment":514},{"nctId":"NCT04086342","phase":"PHASE2","title":"CHI-902 for Treatment of Social Anxiety Disorder","status":"WITHDRAWN","sponsor":"Canopy Growth Corporation","startDate":"2020-01-24","conditions":"Social Anxiety Disorder","enrollment":""},{"nctId":"NCT03049852","phase":"PHASE2","title":"Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium","status":"COMPLETED","sponsor":"Cloudbreak Therapeutics, LLC","startDate":"2017-04-15","conditions":"Pterygium","enrollment":75},{"nctId":"NCT01876550","phase":"PHASE1","title":"A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2013-02","conditions":"Secondarily Infected Traumatic Skin Lesions","enrollment":1902},{"nctId":"NCT03615196","phase":"PHASE1","title":"Study of the Safety of USB005 in Healthy Volunteers","status":"COMPLETED","sponsor":"US Biotest, Inc.","startDate":"2018-07-25","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT02484170","phase":"PHASE1, PHASE2","title":"Mannitol Cream for Post Herpetic Neuralgia","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2015-09-30","conditions":"Neuralgia, Postherpetic","enrollment":20},{"nctId":"NCT03162094","phase":"PHASE1, PHASE2","title":"Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome","status":"UNKNOWN","sponsor":"Avizorex Pharma, S.L.","startDate":"2017-04-03","conditions":"Dry Eye Syndrome","enrollment":172},{"nctId":"NCT03142178","phase":"PHASE1, PHASE2","title":"3VM for Treatment of Chronic Osteoarthritis Knee Pain","status":"COMPLETED","sponsor":"CDA Research Group, Inc.","startDate":"2017-04-30","conditions":"Arthritis, Degenerative","enrollment":150},{"nctId":"NCT02365519","phase":"PHASE2","title":"LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease","status":"COMPLETED","sponsor":"Alcon, a Novartis Company","startDate":"2015-03-09","conditions":"Dry Eye","enrollment":514},{"nctId":"NCT02770248","phase":"PHASE4","title":"24-hr Intraocular Pressure Control With SIMBRINZA ®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2016-05-23","conditions":"Glaucoma","enrollment":162},{"nctId":"NCT02104050","phase":"PHASE2","title":"Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain","status":"COMPLETED","sponsor":"Olatec Therapeutics LLC","startDate":"2014-04","conditions":"Osteoarthritis, Pain","enrollment":202},{"nctId":"NCT01699204","phase":"NA","title":"Diesel Exhaust and Mechanism of Asthma","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2007-09","conditions":"Asthma","enrollment":26},{"nctId":"NCT02756624","phase":"PHASE3","title":"A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2016-04","conditions":"Healthy Subjects","enrollment":516},{"nctId":"NCT00405730","phase":"PHASE3","title":"Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-11","conditions":"Cataracts","enrollment":227},{"nctId":"NCT00695565","phase":"PHASE2","title":"Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy","status":"COMPLETED","sponsor":"Arcion Therapeutics Inc","startDate":"2008-05","conditions":"Painful Diabetic Neuropathy","enrollment":180},{"nctId":"NCT01913106","phase":"PHASE1, PHASE2","title":"HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2007-06","conditions":"Prostatic Neoplasms","enrollment":25},{"nctId":"NCT02782260","phase":"PHASE2","title":"Assessment of the Efficacy of Ocular Dipyridamole in the Treatment of Dry Eye Symptomology in Subjects With Pterygium","status":"UNKNOWN","sponsor":"Ariel University","startDate":"2016-07","conditions":"Dry Eye Syndromes, Pterygium","enrollment":40},{"nctId":"NCT02467543","phase":"PHASE2","title":"The Efficacy of Viburnum Opulus 3X in the Treatment of Primary Dysmenorrhea","status":"COMPLETED","sponsor":"University of Johannesburg","startDate":"2015-02","conditions":"Dysmenorrhea","enrollment":30},{"nctId":"NCT02155543","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-05","conditions":"Healthy Volunteers","enrollment":51},{"nctId":"NCT02076919","phase":"PHASE1","title":"First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-02","conditions":"Age-Related Macular Degeneration","enrollment":110},{"nctId":"NCT02492321","phase":"PHASE3","title":"A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Eleven Biotherapeutics","startDate":"2015-07","conditions":"Allergic Conjunctivitis (AC)","enrollment":250},{"nctId":"NCT00006994","phase":"PHASE3","title":"S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2001-11","conditions":"Cancer-related Problem/Condition, Head and Neck Cancer, Pain","enrollment":23},{"nctId":"NCT01998802","phase":"PHASE3","title":"Phase 3 Study of EBI-005 in Dry Eye Disease","status":"COMPLETED","sponsor":"Eleven Biotherapeutics","startDate":"2014-01","conditions":"Dry Eye Disease (DED)","enrollment":670},{"nctId":"NCT02405039","phase":"PHASE3","title":"Study of EBI-005 in Dry Eye Disease (DED)","status":"UNKNOWN","sponsor":"Eleven Biotherapeutics","startDate":"2015-04","conditions":"Dry Eye","enrollment":188},{"nctId":"NCT00347932","phase":"PHASE3","title":"A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-06","conditions":"Acute Bacterial Conjunctivitis","enrollment":957},{"nctId":"NCT00622908","phase":"PHASE2","title":"Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2004-12","conditions":"Bacterial Conjunctivitis","enrollment":270},{"nctId":"NCT01768975","phase":"PHASE2","title":"Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee","status":"COMPLETED","sponsor":"Olatec Therapeutics LLC","startDate":"2013-01","conditions":"Osteoarthritis of the Knee","enrollment":79},{"nctId":"NCT01670032","phase":"PHASE2, PHASE3","title":"Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo","status":"COMPLETED","sponsor":"NovaBay Pharmaceuticals, Inc.","startDate":"2012-08","conditions":"Impetigo","enrollment":328},{"nctId":"NCT01001091","phase":"PHASE2","title":"AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-12","conditions":"Allergic Conjunctivitis","enrollment":312},{"nctId":"NCT02082899","phase":"PHASE2","title":"A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)","status":"COMPLETED","sponsor":"Eleven Biotherapeutics","startDate":"2014-02","conditions":"Allergic Conjunctivitis","enrollment":150},{"nctId":"NCT01601483","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration","status":"TERMINATED","sponsor":"MacuCLEAR, Inc.","startDate":"2012-10","conditions":"Nonexudative Age Related Macular Degeneration","enrollment":22},{"nctId":"NCT00713349","phase":"PHASE2","title":"Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on Healing","status":"COMPLETED","sponsor":"Healthpoint","startDate":"2008-06","conditions":"Wounds","enrollment":25},{"nctId":"NCT00765700","phase":"PHASE3","title":"Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury","status":"COMPLETED","sponsor":"Imprimis Pharmaceuticals, Inc.","startDate":"2008-09","conditions":"Sprain, Strain, Acute Soft Tissue Injury","enrollment":364},{"nctId":"NCT01175590","phase":"PHASE3","title":"Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-06","conditions":"Bacterial Conjunctivitis","enrollment":518},{"nctId":"NCT01338610","phase":"PHASE2","title":"ESBA105 in Patients With Severe Dry Eye","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-06","conditions":"Eyes Dry Chronic","enrollment":334},{"nctId":"NCT01109173","phase":"PHASE3","title":"Confirmatory Study Nepafenac 0.3%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-06","conditions":"Cataract","enrollment":2120},{"nctId":"NCT00782717","phase":"PHASE2","title":"A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-11","conditions":"Macular Edema","enrollment":263},{"nctId":"NCT00939276","phase":"PHASE3","title":"Macular Edema Incidence/Severity Reduction With Nevanac","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2009-08","conditions":"Diabetic Retinopathy","enrollment":175},{"nctId":"NCT01238783","phase":"PHASE2","title":"Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2011-01","conditions":"Bacterial Conjunctivitis","enrollment":""},{"nctId":"NCT00560638","phase":"PHASE2","title":"Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2005-11","conditions":"Dry Eye","enrollment":119},{"nctId":"NCT01357538","phase":"PHASE4","title":"Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis","status":"COMPLETED","sponsor":"Ursapharm Arzneimittel GmbH","startDate":"2009-02","conditions":"Blepharitis, Signs and Symptoms","enrollment":197},{"nctId":"NCT01223222","phase":"PHASE2","title":"A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection","status":"COMPLETED","sponsor":"Lytix Biopharma AS","startDate":"2010-09","conditions":"Gram-positive, Skin Infections, Mild Eczema/Dermatoses, Atopic Dermatitis","enrollment":24},{"nctId":"NCT00651612","phase":"PHASE3","title":"Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":604}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vehicle"],"phase":"phase_3","status":"active","brandName":"Vehicle (TID)","genericName":"Vehicle (TID)","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}